Stockreport

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia [Yahoo! Finance]

Opus Genetics, Inc.  (IRD) 
PDF Opus Genetics, Inc. FDA PDUFA Goal Date Set for October 17, 2026 RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Opus Genetics , Inc. (Nasdaq: IRD) [Read more]